Free Trial
NYSEAMERICAN:MAIA

MAIA Biotechnology Q3 2024 Earnings Report

MAIA Biotechnology logo
$2.10 +0.04 (+1.94%)
As of 09:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MAIA Biotechnology EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Monday, November 11, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

MAIA Biotechnology's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025

Earnings Documents

MAIA Biotechnology Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA), a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

View MAIA Biotechnology Profile

More Earnings Resources from MarketBeat